Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients Kumar Jeetendra | November 25, 2020 Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the …
Immunomodulatory drugs improve the achievement pace of cancer therapy Kumar Jeetendra | February 15, 2021 Immunomodulatory drugs, for example, Contergan derivatives lenalidomide and pomalidomide, have significantly improved the treatment of hematologic malignancies such as multiple myeloma. Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action within this class of drugs. At exactly the exact same time, they identified new revolutionary targeted cancer therapies. …
Immunotherapy treatments for nephrological autoimmune illnesses may help treat serious Coronavirus Kumar Jeetendra | June 8, 2021 Various viruses and bacteria have been known to cause autoimmune diseases where there’s such a predisposition. This phenomenon also seems to play a major part SARS-CoV-2, especially in severe courses. The body’s own immune cells are activated, with the formation of autoantibodies that attack the body’s own healthy cell structures (proteins, autoantigens); deposits of immune …
